A multi-center, randomized, double-blind, parallel group, placebo controlled, study in patients with non-chronic migraine to assess the efficacy, safety and tolerability of BID oral doses of BGG492 in migraine prevention
Read time: 1 mins
Last updated:9th May 2012
To assess the efficacy of BGG492 vs. placebo in terms of 50% responder rate (defined by ? 50% reduction in attack frequency during the last 4-weeks of the 12-weeks treatment period compared with the 4-weeks Baseline period).
|Study start date||2012-05-09|